We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+0.42%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$6.12B
AUM Growth
+$762M
(+14%)
Cap. Flow
+$908M
Cap. Flow
% of AUM
14.82%
Top 10 Holdings %
Top 10 Hldgs %
15.76%
Holding
794
New
208
Increased
110
Reduced
107
Closed
121
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$85M |
| 2 |
Abbott
ABT
|
+$72M |
| 3 |
NVIDIA
NVDA
|
+$60.9M |
| 4 |
Teradyne
TER
|
+$52.2M |
| 5 |
Legend Biotech
LEGN
|
+$50.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amphenol
APH
|
+$98.7M |
| 2 |
Texas Instruments
TXN
|
+$95.4M |
| 3 |
Global Payments
GPN
|
+$54.3M |
| 4 |
Johnson & Johnson
JNJ
|
+$49.4M |
| 5 |
KLA
KLAC
|
+$49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.26% |
| 2 | Technology | 25.67% |
| 3 | Communication Services | 8.98% |
| 4 | Financials | 5.47% |
| 5 | Consumer Staples | 3.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AUS
201
DELISTED
Austerlitz Acquisition Corporation I
AUS
| $7.46M | 0.12% |
750,000
| – | – |
|
202
Dave Inc
DAVE
$5.07B
| $7.43M | 0.12% |
23,438
| – | – |
|
203
System1
SST
$14.5M
| $7.43M | 0.12% |
+75,000
| New | +$7.43M |
|
204
Keros Therapeutics
KROS
$200M
| $7.43M | 0.12% |
+187,835
| New | +$6.68M |
|
|
GCAC
205
DELISTED
Growth Capital Acquisition Corp. Class A Common Stock
GCAC
| $7.41M | 0.12% |
+750,000
| New | +$7.38M |
|
|
RACB
206
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $7.39M | 0.12% |
750,000
| – | – |
|
|
NARI
207
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $7.33M | 0.12% |
+90,438
| New | +$7.6M |
|
208
Freshpet
FRPT
$2.93B
| $7.29M | 0.12% |
51,095
+4,244
| +9% | +$607K |
|
209
Tenet Healthcare
THC
$20.1B
| $7.22M | 0.12% |
108,628
-57,362
| -35% | -$4.07M |
|
|
MAAC
210
DELISTED
Montes Archimedes Acquisition Corp. Class A Common Stock
MAAC
| $7.19M | 0.12% |
+718,963
| New | +$7.14M |
|
211
Perrigo
PRGO
$1.48B
| $7.18M | 0.12% |
151,639
| – | – |
|
212
Zai Lab
ZLAB
$2.05B
| $7.03M | 0.11% |
66,660
-18,399
| -22% | -$2.64M |
|
213
Acumen Pharmaceuticals
ABOS
$157M
| $6.97M | 0.11% |
+468,794
| New | +$7.8M |
|
|
CLYM
214
Climb Bio
CLYM
$676M
| $6.96M | 0.11% |
+387,224
| New | +$8M |
|
|
HLGN
215
DELISTED
Heliogen, Inc.
HLGN
| $6.91M | 0.11% |
19,901
+10,615
| +114% | +$3.68M |
|
216
Invivyd
IVVD
$163M
| $6.82M | 0.11% |
+161,459
| New | +$5.99M |
|
217
Akebia Therapeutics
AKBA
$351M
| $6.69M | 0.11% |
2,323,517
+2,199,743
| +1,777% | +$6.28M |
|
218
Encompass Health
EHC
$11.2B
| $6.61M | 0.11% |
110,762
+23,483
| +27% | +$1.48M |
|
219
Centene
CNC
$31.5B
| $6.57M | 0.11% |
105,420
-49,597
| -32% | -$3.31M |
|
220
Atea Pharmaceuticals
AVIR
$369M
| $6.5M | 0.11% |
185,265
-2,540
| -1% | -$70.5K |
|
221
Janux Therapeutics
JANX
$934M
| $6.49M | 0.11% |
300,031
-34,229
| -10% | -$985K |
|
|
ZGNX
222
DELISTED
Zogenix, Inc.
ZGNX
| $6.47M | 0.11% |
426,140
-315,419
| -43% | -$4.93M |
|
223
Tango Therapeutics
TNGX
$4.43B
| $6.47M | 0.11% |
500,040
-3,357
| -0.7% | -$40.2K |
|
224
Tyra Biosciences
TYRA
$1.91B
| $6.44M | 0.11% |
+366,035
| New | +$7M |
|
225
Century Therapeutics
IPSC
$357M
| $6.29M | 0.1% |
250,094
-31,632
| -11% | -$856K |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q3 2021 Portfolio in Review
As of Q3 2021, Woodline Partners held 794 positions worth $6.12B, up 14% from $5.36B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Woodline Partners deployed $908M of net new capital in Q3 2021, opening 208 new positions and adding to 110 existing holdings. Its largest new stake was Qualcomm: 599,018 shares worth $77.3M.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 47% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Amphenol, an estimated $98.7M trimmed.
- Woodline Partners's largest Q3 2021 buy was Qualcomm: 599,018 shares worth $77.3M.
- Woodline Partners added most to Teradyne in Q3 2021, an estimated $52.2M increase.
- Woodline Partners's biggest Q3 2021 reduction was Amphenol, cutting an estimated $98.7M.
- Woodline Partners fully exited Boston Scientific in Q3 2021, selling an estimated $44.9M.
- Woodline Partners's ten largest holdings make up 16% of its $6.12B portfolio in Q3 2021.
- Woodline Partners opened 208 new positions and closed 121 in Q3 2021.
- Woodline Partners's portfolio value rose 14% quarter-over-quarter to $6.12B.
Based on Woodline Partners's 13F filing for Q3 2021, filed 15 Nov 2021.